BridgeBio Pharma, Inc. (NASDAQ:BBIO) Q1 2025 Earnings Call Transcript
Operator: Good afternoon. I will be your conference operator today. All lines have been placed on mute to prevent any background noise.
Bridgebio Pharma Inc. (BBIO)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | BIT Capital GmbH Jan Beckers | 557,646 | $19,277,822 | +103% | 1.65% |
| 2. | Royce & Associates Chuck Royce | 191,782 | $6,629,904 | +33% | 0.07% |
| 3. | HealthInvest Partners AB Anders Hallberg And Carl Bennet | 151,348 | $5,232,100 | +47% | 2.31% |
| 4. | 2,700,000 | $3,099,816 | +4% | 0.16% | |
| 5. | CaaS Capital Frank Fu | 8,600 | $297,302 | 0.03% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $12.68 | 1,542 | 3,433 | 2021-12-28 | Filing | ||
| $13.18 | 1,891 | 1,891 | 2021-12-28 | Filing | ||
| $12.68 | 1,542 | 3,433 | 2021-12-28 | Filing | ||
| $13.18 | 1,891 | 1,891 | 2021-12-28 | Filing | ||
| $8.39 | 12,000 | Director | 12,000 | 2022-03-15 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $38.51 | 1,026 | 147,639 | 2025-05-02 | Filing | ||
| $38.50 | 100,000 | 105,583 | 2025-05-02 | Filing | ||
| $34.11 | 75,000 | 4,873,447 | 2025-04-22 | Filing | ||
| $35.00 | 10,000 | 12,000 | 2025-04-14 | Filing | ||
| $34.05 | 30,000 | 12,000 | 2025-04-01 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 14,900,145 | $515,098,014 | 0.01% | |
| 2. | 13,357,496 | $461,768,637 | 0.01% | |
| 3. | 2,388,308 | $82,563,807 | 0.01% | |
| 4. | 2,090,268 | $72,415,185 | 0.08% | |
| 5. | 70,404 | $63,469,206 | 2.46% |
News See All
Billionaire Andreas Halvorsen's 10 Stock Picks With Huge Upside Potential
Ole Andreas Halvorsen is one of the prominent names among former employees of Julian Robertson's Tiger Management.
10 Best Mid Cap Biotech Stocks to Buy
On March 6, Jared Holz, Mizuho health care equity strategist, appeared on CNBC's 'Power Lunch' to discuss investing in biotech and the oversaturation in the sector.
10 Best Performing Mid Cap Stocks to Buy According to Analysts
On February 7, Simeon Hyman, Global Investment Strategist at ProShares Advisors, appeared on CNBC to discuss the upcoming jobs report and its expected impact on the market.
10 Best Performing Pharma Stocks So Far in 2025
On February 20, Jared Holz, Mizuho healthcare sector strategist, appeared on 'Squawk Box' to discuss the potential challenges and opportunities the pharmaceutical industry may face under the new Trump...
12 Best Healthcare Stocks to Buy According to Analysts
McKinsey reported that, since 2019, the US healthcare industry witnessed significant financial pressure.
10 Unstoppable Stocks to Buy in 2025
As per the recent earnings update by FactSet dated 24th January 2025, the Q4 2024 earnings season for the S&P 500 has seen a strong start.
Why These 15 Stocks Are Skyrocketing in 2025
Stock gains always get people talking, and 2025 is no exception. Markets have moved higher for a while due to a shift toward tech innovation.
Billionaire Andreas Halvorsen's Top 15 Long-Term Stock Picks
Andreas Halvorsen is a prominent Norwegian hedge fund manager and the co-founder of Viking Global, one of the most successful equity-focused hedge funds in the world.
10 Worst Performing Biotech Stocks in 2024
Biotechnology stocks are among the most volatile in the market due to their high risk.
Billionaire Hedge Funds
